Scientist have been facing numerous challenges in the development of an effective therapeutic strategy for the treatment of COVID-19 pneumonia. Improving patient immunity and reducing lung injury induced by COVID -19 is of great significance. Our small sample clinical study (7 patient) showed that nebulization mesenchymal stem cells (MSCs) exosomes is a new method to treat COVID-19 pneumonia. Nebulization MSCs exosomes did not induce acute allergic reaction and no secondary allergic reaction. It can reduce the levels of C-reactive protein in plasma, promote the absorption of pulmonary lesions, and reduced the time of hospitalization for COVID-19 pneumonia patients. Nebulization MSCs exosomes is a safe, effective and simple method. Using nebulization MSCs exosomes from the beginning of the treatment may benefit patients more.o 350 words. No references allowed. Abstracts may be submitted at a later date.


- Journal
- Articles
- Author Center
- Society
Editorial Board
The ESMED Editorial Board is comprised of experts from around the world.
Meet the community
See what our members have been working on.
Membership
Join ESMED for access to member-only content, congress discounts, and more.
- Policy